{"downloaded": true, "htmlmade": false, "full": {"id": "30054307", "source": "MED", "pmid": "30054307", "pmcid": "PMC6093727", "fullTextIdList": {"fullTextId": "PMC6093727"}, "doi": "10.1182/bloodadvances.2018019224", "title": "Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.", "authorString": "Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD.", "authorList": {"author": [{"fullName": "Loghavi S", "firstName": "Sanam", "lastName": "Loghavi", "initials": "S", "authorId": {"@type": "ORCID", "#text": "0000-0001-8980-3202"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematopathology."}}}, {"fullName": "Sui D", "firstName": "Dawen", "lastName": "Sui", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Biostatistics, and."}}}, {"fullName": "Wei P", "firstName": "Peng", "lastName": "Wei", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Biostatistics, and."}}}, {"fullName": "Garcia-Manero G", "firstName": "Guillermo", "lastName": "Garcia-Manero", "initials": "G", "authorId": {"@type": "ORCID", "#text": "0000-0002-3631-2482"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX."}}}, {"fullName": "Pierce S", "firstName": "Sherry", "lastName": "Pierce", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX."}}}, {"fullName": "Routbort MJ", "firstName": "Mark J", "lastName": "Routbort", "initials": "MJ", "authorId": {"@type": "ORCID", "#text": "0000-0003-4860-261X"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematopathology."}}}, {"fullName": "Jabbour EJ", "firstName": "Elias J", "lastName": "Jabbour", "initials": "EJ", "authorId": {"@type": "ORCID", "#text": "0000-0003-4465-6119"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX."}}}, {"fullName": "Pemmaraju N", "firstName": "Naveen", "lastName": "Pemmaraju", "initials": "N", "authorId": {"@type": "ORCID", "#text": "0000-0002-1670-6513"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX."}}}, {"fullName": "Kanagal-Shamanna R", "firstName": "Rashmi", "lastName": "Kanagal-Shamanna", "initials": "R", "authorId": {"@type": "ORCID", "#text": "0000-0001-7829-5249"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematopathology."}}}, {"fullName": "Gur HD", "firstName": "H Deniz", "lastName": "Gur", "initials": "HD", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematopathology."}}}, {"fullName": "Hu S", "firstName": "Shimin", "lastName": "Hu", "initials": "S", "authorId": {"@type": "ORCID", "#text": "0000-0001-7110-3814"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematopathology."}}}, {"fullName": "Zuo Z", "firstName": "Zhuang", "lastName": "Zuo", "initials": "Z", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematopathology."}}}, {"fullName": "Medeiros LJ", "firstName": "L Jeffrey", "lastName": "Medeiros", "initials": "LJ", "authorId": {"@type": "ORCID", "#text": "0000-0001-6577-8006"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematopathology."}}}, {"fullName": "Kantarjian HM", "firstName": "Hagop M", "lastName": "Kantarjian", "initials": "HM", "authorId": {"@type": "ORCID", "#text": "0000-0002-1908-3307"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX."}}}, {"fullName": "Khoury JD", "firstName": "Joseph D", "lastName": "Khoury", "initials": "JD", "authorId": {"@type": "ORCID", "#text": "0000-0003-2621-3584"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematopathology."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-6577-8006"}, {"@type": "ORCID", "#text": "0000-0001-7110-3814"}, {"@type": "ORCID", "#text": "0000-0001-7829-5249"}, {"@type": "ORCID", "#text": "0000-0001-8980-3202"}, {"@type": "ORCID", "#text": "0000-0002-1670-6513"}, {"@type": "ORCID", "#text": "0000-0002-1908-3307"}, {"@type": "ORCID", "#text": "0000-0002-3631-2482"}, {"@type": "ORCID", "#text": "0000-0003-2621-3584"}, {"@type": "ORCID", "#text": "0000-0003-4465-6119"}, {"@type": "ORCID", "#text": "0000-0003-4860-261X"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "15", "volume": "2", "journalIssueId": "2710511", "dateOfPublication": "2018 Aug", "monthOfPublication": "8", "yearOfPublication": "2018", "printPublicationDate": "2018-08-01", "journal": {"title": "Blood advances", "ISOAbbreviation": "Blood Adv", "medlineAbbreviation": "Blood Adv", "NLMid": "101698425", "ISSN": "2473-9529", "ESSN": "2473-9537"}}, "pubYear": "2018", "pageInfo": "1807-1816", "abstractText": "The 2017 revision of the World Health Organization (WHO) classification includes substantial changes to the subclassification of chronic myelomonocytic leukemia (CMML): (1) a 3-tiered blast-based scheme including a novel \"CMML-0\" category replacing a 2-tiered system in place since 2001 and (2) 2 CMML subtypes, myelodysplastic (MDS-CMML) and myeloproliferative (MP-CMML), based on a white blood cell count cutoff of 13 \u00d7 10<sup>9</sup>/L. The clinical utility of this subclassification scheme, particularly the expansion of blast-based subgroups, has not been validated. In this study, a large single-institution CMML patient cohort (n = 629) was used to assess the prognostic impact of the newly proposed categories. Patients were risk stratified according to the CMML-specific Prognostic Scoring System (CPSS) and the MD Anderson Prognostic Scoring System. MP-CMML patients had significantly shorter overall survival (OS; <i>P</i> < .0001; hazard ratio: 0.53, 95% confidence interval: 0.42-0.65) and median duration to acute myeloid leukemia (AML) transformation (<i>P</i> < .0001; 15.2 vs 22.0 months) compared with MDS-CMML patients. The CMML-0 group included 36.4% patients with higher risk CPSS categories and 11.2% of patients with high-risk cytogenetics. Among treatment-na\u00efve patients (n = 499), there was a marginal difference in OS between the CMML-0 and CMML-1<sup>2017</sup> subgroups (<i>P</i> = .0552). The WHO 2017 blast-based categories were not associated with AML-free survival. Incorporation of the WHO 2017 blast-based subgroups in a modified CPSS scheme had a neutral effect and did not improve its prognostic strength. Our data support the inclusion of MP-CMML and MDS-CMML subtypes in the WHO 2017 revision. Although of some utility in MP-CMML, the 3-tiered blast-based system is not well supported in this study.", "affiliation": "Department of Hematopathology.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Clinical Trial", "research-article", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Blast Crisis", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CL", "qualifierName": "classification", "majorTopic_YN": "N"}, {"abbreviation": "DI", "qualifierName": "diagnosis", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Disease-Free Survival"}, {"majorTopic_YN": "N", "descriptorName": "Survival Rate"}, {"majorTopic_YN": "N", "descriptorName": "Risk Assessment"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "World Health Organization"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CL", "qualifierName": "classification", "majorTopic_YN": "Y"}, {"abbreviation": "DI", "qualifierName": "diagnosis", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "Y"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/bloodadvances.2018019224"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6093727"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6093727?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/bloodadvances.2018019224"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "6", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2019-04-03", "dateOfCreation": "2018-07-29", "firstIndexDate": "2018-07-29", "fullTextReceivedDate": "2020-07-11", "dateOfRevision": "2019-04-03", "firstPublicationDate": "2018-08-01"}, "abstract": "The 2017 revision of the World Health Organization (WHO) classification includes substantial changes to the subclassification of chronic myelomonocytic leukemia (CMML): (1) a 3-tiered blast-based scheme including a novel \"CMML-0\" category replacing a 2-tiered system in place since 2001 and (2) 2 CMML subtypes, myelodysplastic (MDS-CMML) and myeloproliferative (MP-CMML), based on a white blood cell count cutoff of 13 \u00d7 10<sup>9</sup>/L. The clinical utility of this subclassification scheme, particularly the expansion of blast-based subgroups, has not been validated. In this study, a large single-institution CMML patient cohort (n = 629) was used to assess the prognostic impact of the newly proposed categories. Patients were risk stratified according to the CMML-specific Prognostic Scoring System (CPSS) and the MD Anderson Prognostic Scoring System. MP-CMML patients had significantly shorter overall survival (OS; <i>P</i> < .0001; hazard ratio: 0.53, 95% confidence interval: 0.42-0.65) and median duration to acute myeloid leukemia (AML) transformation (<i>P</i> < .0001; 15.2 vs 22.0 months) compared with MDS-CMML patients. The CMML-0 group included 36.4% patients with higher risk CPSS categories and 11.2% of patients with high-risk cytogenetics. Among treatment-na\u00efve patients (n = 499), there was a marginal difference in OS between the CMML-0 and CMML-1<sup>2017</sup> subgroups (<i>P</i> = .0552). The WHO 2017 blast-based categories were not associated with AML-free survival. Incorporation of the WHO 2017 blast-based subgroups in a modified CPSS scheme had a neutral effect and did not improve its prognostic strength. Our data support the inclusion of MP-CMML and MDS-CMML subtypes in the WHO 2017 revision. Although of some utility in MP-CMML, the 3-tiered blast-based system is not well supported in this study.", "journaltitle": "Blood advances", "authorinfo": ["Loghavi S", "Sui D", "Wei P", "Garcia-Manero G", "Pierce S", "Routbort MJ", "Jabbour EJ", "Pemmaraju N", "Kanagal-Shamanna R", "Gur HD", "Hu S", "Zuo Z", "Medeiros LJ", "Kantarjian HM", "Khoury JD"], "title": "Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories."}